Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
June 25, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Stock code: 600276 Stock abbreviation: Hengrui Pharma No.: Lin 2026-091

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announcement in Relation to the Approval for Drug Registration

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Recently, a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (江蘇恒瑞醫藥股份有限公司) (the "Company"), Shanghai Suncadia Medicine Co., Ltd. (上海盛迪醫藥有限公司), received a notification from the National Medical Products Administration (hereinafter referred to as the "NMPA") approving a new indication for adebrelimab injection. This marks the second indication approved for adebrelimab in lung cancer and makes adebrelimab the first domestically produced PD-L1 inhibitor approved in China for the perioperative indication for NSCLC. The relevant information is hereby announced as follows:

I. Basic Information of the Drug

Drug name: Adebrelimab injection

Dosage form: Injection

Strength: 600 mg (12 mL)/bottle

Registered Category: Class 2.2 Therapeutic Biological Product

Acceptance No.: CXSS2500099

Prescription/over-the-counter drug: Prescription drug

Approved indication: This product is indicated for use in combination with platinum-based chemotherapy as neoadjuvant therapy, followed by continued use as

monotherapy as adjuvant therapy after surgery, for the treatment of adult patients with resectable stage II, IIIA, and IIIB non-small cell lung cancer (NSCLC) who have no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.

II. Previously Approved Indications of the Drug

Adebrelimab injection was previously approved for marketing in February 2023, with the approved indication being in combination with carboplatin and etoposide for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

III. Other Information of the Drug

The latest report on the disease burden of cancer in China shows that lung cancer is the malignant tumor with the highest incidence and mortality in China[2], among which NSCLC is the predominant pathological subtype, accounting for about 80% to 85% of all lung cancer cases. Radical surgical resection is the primary treatment modality for early-stage NSCLC; however, postoperative recurrence remains a clinical challenge. A meta-analysis (CHEST study) including 1,060 surgical study groups showed that, even after successful tumor resection, more than half (50–66%) of patients with stage II–III disease may still face a risk of recurrence within the next five years[3]. Although perioperative chemotherapy (neoadjuvant or adjuvant chemotherapy) has been introduced into clinical practice, it only improves the 5-year survival rate by about 5%[4,5], highlighting an urgent clinical need for more effective systemic treatment options. In recent years, breakthroughs in the field of immunotherapy have provided new options for early-stage NSCLC treatment. Multiple domestic and international phase III studies on perioperative immunotherapy have demonstrated that incorporating immunotherapy into neoadjuvant and adjuvant treatment phases can bring significant survival benefits to patients, and this approach has now been recommended as a new standard by authoritative clinical guidelines both in China and globally[6].

This new indication approval for adebrelimab is based on the interim analysis results of the phase III stage of a randomized, double-blind, multicenter phase Ib/III clinical study (SHR-1316-III-303) led by Professor Yilong Wu from Guangdong

Provincial People's Hospital[1]. Data showed that the major pathological response (MPR) rate in the adebrelimab injection plus chemotherapy group reached 53.8%, nearly three times that of the control group; the 2-year event-free survival (EFS) rate was 74.8%, representing a significant 48% reduction in the risk of disease recurrence, progression, or death; and the surgery rate was as high as 88.8%. The adebrelimab plus chemotherapy group achieved statistically significant and clinically meaningful improvements in both primary endpoints, MPR and EFS, with a favorable overall safety profile and no new safety signals identified[1].

Adebrelimab injection is a humanized anti-PD-L1 monoclonal antibody independently developed by the Company. It specifically binds to the PD-L1 molecule, thereby blocking the PD-1/PD-L1 pathway that leads to tumor immune tolerance, and reactivates the anti-tumor activity of the immune system to achieve therapeutic effects against tumors. Comparable overseas products include atezolizumab (trade name: Tecentriq), avelumab (trade name: Bavencio), and durvalumab (trade name: Imfinzi), all of which have been approved for marketing and sale in the United States. Among these, atezolizumab and durvalumab have also been approved for marketing in China. In addition, several other similar products have been approved for marketing in China. After review of available information, the combined global sales of Atezolizumab, Avelumab, and Durvalumab in 2025 amounted to approximately USD 11.054 billion. As of the present date, the cumulative research and development investment in the adebrelimab injection-related projects is approximately RMB 1,225.10 million.

IV.Risk Warning

The Company places great importance on drug R&D, and strictly controls the quality and safety throughout the processes of drug R&D, manufacture, and sales. However, post-approval production and sales may be subject to uncertainties. Investors are kindly advised to make prudent decisions and pay attention to investment risks.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

1. Yi-Long Wu, et al. Perioperative adebrelimab (A) plus chemotherapy (chemo) in resectable stage II-III NSCLC: phase 3 EFS interim analysis (IA) and molecular residual disease (MRD) analysis. 2026 AACR Annual Meeting. Abstract CT014.

2. Rongshou Zheng, Ru Chen, Bingfeng Han, et al. Cancer incidence and mortality in China, 2022 [J]. Chinese Journal of Oncology, 2024, 46(3):221-231.

3. Ravi, et al. Chest. 2024;165:1260.

4. NSCLC Meta-analysis Collaborative Group. Lancet. 2014;383:1561-1571.

5. NSCLC Meta-analysis Collaborative Group. Lancet. 2010;375:1267-1277.

6. Chinese Society of Clinical Oncology (CSCO). Guidelines on Diagnosis and Treatment of Non-Small Cell Lung Cancer, 2025 Edition.